MedTrace Logo

Clinical Sensitivity of Clearview Rapid Tests in 12-17 y/o Pediatric Population

NCT00567749 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2008-06-27

No results posted yet for this study

Summary

This study is to establish the clinical sensitivity of the Chembio Diagnostics Systems, Inc. Clearview COMPLETE HIV 1/2 Assay and Clearview HIV 1/2 Stat-Pak Assay (Clearview HIV tests) in pediatric subjects who are between 12 and 17 years of age. A minimum of ten (10) known HIV-positive participants will be tested.

Conditions

  • HIV Infections

Sponsors & Collaborators

  • Inverness Medical Innovations

    collaborator INDUSTRY

  • University of Maryland

    collaborator OTHER

  • Focus Diagnostics, Inc.

    collaborator INDUSTRY

  • Chembio Diagnostic Systems, Inc.

    lead INDUSTRY

Principal Investigators

  • Neil T. Constantine, Ph.D. · University of Maryland, Baltimore

Eligibility

Min Age
12 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00567749 on ClinicalTrials.gov